The Application Of Ticagrelor In High Risk Patients With Non-revascularzation Of Acute Coronary Syndrome

Objective: To observe the efficacy and safety evaluation of ticagrelor in high risk patients with non-revascularzation of acute coronary syndromeMethods: Eighty-one patients with acute coronary syndrome with a SYNTAX score of ?33 after coronary angiography and without revascularization were included.There were 40 patients in the control group with clopidogrel and aspirin,41 patients in the trial group with ticagrelor and aspirin.Observe the inhibitory rate of platelet aggregation,fibrinogen(Fib),absolute sum of ST-segment changes of ECG(?ST level),Canadian Cardiovascular Society class,left ventricular ejection fraction(LVEF),and type B brain at admission and different time after drug treatment.Changes in natriuretic peptide(BNP)and incidence of major adverse cardiac events(MACE)and adverse events within 6 months.Results: Inhibitory rate of platelet aggregation,,Fib,?ST,Canadian Cardiovascular Society class,LVEF and BNP were not statistically different between admissions(P>0.05);Inhibitory rate of platelet aggregation at 7 days,1 month and 6 months after drug treatment,the experimental group was significantly higher than that of the control group(P<0.05).After 7 days and 1month of drug treatment,Fib and ?ST were lower in the experimental group than in the control group(P<0.05).There was a statistically significant difference in the composition ratio of the experimental group and control group between 1 month and 6 months after treatment in Canadian Cardiovascular Society Class(P<0.05),while the LVEF and BNP test groups were superior to the control group,but there was no significant difference(P>0.05).The incidence of MACE was lower in the experimental group than in the control group within 6 months.The incidence of bleeding and dyspnea was higher in the experimental group than in the control group,but none of themajor bleeding and severe dyspnea occurred.Conclusion: Ticagrelor is better than clopidogrel in inhibitory rate of platelet aggregation,Fib,improving myocardial ischemia,and improving heart function.It can reduce the incidence of MACE in the near and middle period and does not increase the risk of major bleeding.Clinical application is relatively safe.